A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)

Trial Identifier: ACE-ST-209
Sponsor:AcertaPharma
NCTID:NCT02586857
Start Date:January 2016
Primary Completion Date: June 2020
Study Completion Date: December 2025
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

LanguageDescription
English Version

Trial Locations

CountryLocation
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 2215
US, MA Boston, MA, US, 02114
US, CA Los Angeles, CA, US, 90095-1769
US, CA Palo Alto, CA, US, 94304
US, NY New York, NY, US, 10021
US, WA Vancouver, WA, US, 98684